RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE

<p>Aim. Тo evaluate compliance of ongoing antithrombotic therapy (ATT) in various forms of atrial fibrillation (AF) with the risk level of thromboembolic complications (TEC), calculated with the СHADS2 and CHA2DS2–VASc scales in real clinical practice. Material and methods. A retrospective stu...

Full description

Bibliographic Details
Main Authors: I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/581
id doaj-8d30d919592e41f7a241c4d8ed122284
record_format Article
spelling doaj-8d30d919592e41f7a241c4d8ed1222842020-11-24T22:08:57ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-12-018567568010.1234/1819-6446-2012-5-675-680580RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICEI. V. Grajfer0L. E. Kuvshinova1P. V. Dolotovskaya2O. V. Reshet'ko3N. V. Furman4Саратовский государственный медицинский университет им. В.И. РазумовскогоСаратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологииСаратовский государственный медицинский университет им. В.И. РазумовскогоСаратовский научно-исследовательский институт кардиологии<p>Aim. Тo evaluate compliance of ongoing antithrombotic therapy (ATT) in various forms of atrial fibrillation (AF) with the risk level of thromboembolic complications (TEC), calculated with the СHADS2 and CHA2DS2–VASc scales in real clinical practice. Material and methods. A retrospective study of hospital records of 308 in-patients admitted to the cardiology departments of two multidisciplinary hospitals during the year because of nonvalvular AF . Risk of thromboembolic complications was estimated with the CHADS2 and CHA2DS2–VASc scales and appointed ATT was analyzed. Results. Patients with high risk of TEC were predominated in the study population: 77.6% and 91.9% according to CHADS2 and CHA2DS2–VASc scales, respectively. Moderate risk was found in  17.6%  and  6.1%  of  patients  according  to  CHADS2 and  CHA2DS2–VASc  scales,  respectively.  Only  32.2%  and  28.6%  28.6%  of  patients  at  high  risk  according  to  CHADS2 and  CHA2DS2–VASc scales, respectively received warfarin in hospital. All patients with permanent AF in this sample had a high risk of TEC according to the both scales. In the group of paroxysmal/persistent AF the high, moderate and low risk of TEC was identified in 87%, 9.9%, and 3.1% of patients, respectively , according to CHA2DS2–VASc scale and in 64.25%, 28.5% and 7.5% of patients, respectively , according to CHADS2 scale. Difference in high-risk patient rate was not significant among patients with permanent AF . In high risk group contraindications for receiving indirect anticoagulants were more frequent in the group with permanent AF (OR 3.1; 95% CI 0.88–10.7; p&gt;0,05). The probability of warfarin prescription in patients with permanent AF was higher than in patients with paroxysmal or persistent AF (OR 1.98, 95% CI 1,18-3,31), and probability of aspirin prescription was lower (OR 0.82; 95% CI 0,51-1,32; p&gt;0,05).  Conclusion. In real clinical practice oral anticoagulants are prescribed insufficiently in patients at high risk. Usage of CHA2DS2–VASc scale compared with usage of CHADS2 scale, leads to significant increase in the proportion of patients at high risk due to reduction in the proportion of patients with moderate risk in persistent or permanent AF . Usage of CHADS2 scale can lead to an underestimation of the TEC risk in patients with persistent or permanent AF .</p>http://www.rpcardio.ru/jour/article/view/581фибрилляция предсердийстратификация рискатромбоэмболические осложненияантитромботическая терапия
collection DOAJ
language English
format Article
sources DOAJ
author I. V. Grajfer
L. E. Kuvshinova
P. V. Dolotovskaya
O. V. Reshet'ko
N. V. Furman
spellingShingle I. V. Grajfer
L. E. Kuvshinova
P. V. Dolotovskaya
O. V. Reshet'ko
N. V. Furman
RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
Racionalʹnaâ Farmakoterapiâ v Kardiologii
фибрилляция предсердий
стратификация риска
тромбоэмболические осложнения
антитромботическая терапия
author_facet I. V. Grajfer
L. E. Kuvshinova
P. V. Dolotovskaya
O. V. Reshet'ko
N. V. Furman
author_sort I. V. Grajfer
title RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
title_short RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
title_full RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
title_fullStr RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
title_full_unstemmed RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
title_sort risk of thromboembolic complications and antithrombotic therapy in in-patients with permanent and recurrent atrial fibrillation in real clinical practice
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-12-01
description <p>Aim. Тo evaluate compliance of ongoing antithrombotic therapy (ATT) in various forms of atrial fibrillation (AF) with the risk level of thromboembolic complications (TEC), calculated with the СHADS2 and CHA2DS2–VASc scales in real clinical practice. Material and methods. A retrospective study of hospital records of 308 in-patients admitted to the cardiology departments of two multidisciplinary hospitals during the year because of nonvalvular AF . Risk of thromboembolic complications was estimated with the CHADS2 and CHA2DS2–VASc scales and appointed ATT was analyzed. Results. Patients with high risk of TEC were predominated in the study population: 77.6% and 91.9% according to CHADS2 and CHA2DS2–VASc scales, respectively. Moderate risk was found in  17.6%  and  6.1%  of  patients  according  to  CHADS2 and  CHA2DS2–VASc  scales,  respectively.  Only  32.2%  and  28.6%  28.6%  of  patients  at  high  risk  according  to  CHADS2 and  CHA2DS2–VASc scales, respectively received warfarin in hospital. All patients with permanent AF in this sample had a high risk of TEC according to the both scales. In the group of paroxysmal/persistent AF the high, moderate and low risk of TEC was identified in 87%, 9.9%, and 3.1% of patients, respectively , according to CHA2DS2–VASc scale and in 64.25%, 28.5% and 7.5% of patients, respectively , according to CHADS2 scale. Difference in high-risk patient rate was not significant among patients with permanent AF . In high risk group contraindications for receiving indirect anticoagulants were more frequent in the group with permanent AF (OR 3.1; 95% CI 0.88–10.7; p&gt;0,05). The probability of warfarin prescription in patients with permanent AF was higher than in patients with paroxysmal or persistent AF (OR 1.98, 95% CI 1,18-3,31), and probability of aspirin prescription was lower (OR 0.82; 95% CI 0,51-1,32; p&gt;0,05).  Conclusion. In real clinical practice oral anticoagulants are prescribed insufficiently in patients at high risk. Usage of CHA2DS2–VASc scale compared with usage of CHADS2 scale, leads to significant increase in the proportion of patients at high risk due to reduction in the proportion of patients with moderate risk in persistent or permanent AF . Usage of CHADS2 scale can lead to an underestimation of the TEC risk in patients with persistent or permanent AF .</p>
topic фибрилляция предсердий
стратификация риска
тромбоэмболические осложнения
антитромботическая терапия
url http://www.rpcardio.ru/jour/article/view/581
work_keys_str_mv AT ivgrajfer riskofthromboemboliccomplicationsandantithrombotictherapyininpatientswithpermanentandrecurrentatrialfibrillationinrealclinicalpractice
AT lekuvshinova riskofthromboemboliccomplicationsandantithrombotictherapyininpatientswithpermanentandrecurrentatrialfibrillationinrealclinicalpractice
AT pvdolotovskaya riskofthromboemboliccomplicationsandantithrombotictherapyininpatientswithpermanentandrecurrentatrialfibrillationinrealclinicalpractice
AT ovreshetko riskofthromboemboliccomplicationsandantithrombotictherapyininpatientswithpermanentandrecurrentatrialfibrillationinrealclinicalpractice
AT nvfurman riskofthromboemboliccomplicationsandantithrombotictherapyininpatientswithpermanentandrecurrentatrialfibrillationinrealclinicalpractice
_version_ 1725813725133275136